Clearside Biomedical Announces Option Exercise by REGENXBIO for Global License for Use of SCS Microinjector(TM) in AAV Gene Therapy Delivery

Stock Information for Clearside Biomedical Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Clearside Biomedical Inc.

Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Clearside Biomedical Appoints Victor Chong, M.D., MBA as Chief Medical Officer
Clearside Biomedical Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024
Clearside Biomedical Announces Pricing of $15 Million Registered Direct Offering
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.